Gossamer Bio, Inc.
$0.16
The Read: Gossamer Bio's stock historically plunged after its Phase 3 PROSERA trial failed to show strong efficacy or safety, then collapsed further on a dilutive equity raise, and dropped again amid legal turmoil and lack of a clear recovery plan.
Price
Overlays
Panel
GOSS
Hover to view data
No Data